Shire makes agreed bid for Jerini AG

Shire Plc, the British specialty pharmaceutical company, has made an agreed bid to acquire all of the Frankfurt-listed shares of Jerini Ag for €328 million. In a conference call on 3 July 2008, Shire’s chief executive, Angus Russell, said the acquisition will add Jerini’s hereditary angioedema (HAE) product, Firazyr (icatibant acetate), to its portfolio of drugs for symptomatic rare disorders administered by specialist physicians. Firazyr was given a positive opinion by the European Medicine Agency’s Committee for Medicinal Products for Human Use in April 2008 and is awaiting final approval by the European Commission.

New product warnings from the EMEA

The European Medicines Agency (EMEA) has said that new or strengthened warnings should be included in the product information for three groups of marketed pharmaceutical products: epoetin-containing medicines, ergot-derived dopamine agonists and etoricoxib-containing medicines.

CHMP recommends three products, turns down another

The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommended that the following drugs be given a marketing authorisation, subject to confirmation by the European Commission.

Pharmexa replaces its CEO amid further cost cuts

Pharmexa A/S, the Danish company that is developing cancer vaccines, has replaced its chief executive officer while announcing a further 40% staff reduction in addition to a 20% staff cut in February 2008.

EMEA and FDA strengthen their ties

The European Medicines Agency and the US Food and Drug Administration plan to broaden the scope of a five-year old agreement which enables them to share confidential information submitted to them by pharmaceutical companies.